Omeprazole


Description

Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized...

Read more

Pharmacology

Indication

Omeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the fol... Read more

Pharmacodynamic

**Effects on gastric acid secretion**

This drug decreases gastric acid secretion [FDA label]. Aft...
Read more

Mechanismofaction

Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K... Read more

Absorption

Omeprazole delayed-release capsules contain an enteric-coated granule formulation of omeprazole (bec... Read more

Proteinbinding

Approximately 95% bound to human plasma proteins [FDA label].

Volumeofdistribution

Approximately 0.3 L/kg, corresponding to the volume of extracellular water [ Read more

Clearance

Healthy subject (delayed release capsule), total body clearance 500 - 600 mL/min [FDA label]Geriatri... Read more

Halflife

0.5-1 hour (healthy subjects, delayed-release capsule) [FDA label]
Approximately 3 hours (hepatic...
Read more

Routeofelimination

After a single dose oral dose of a buffered solution of omeprazole, negligible (if any) amounts of u... Read more

Toxicity

**Oral acute (LD50)**: 4000 mg/kg (mouse), 2210 mg/kg (rat) [MSDS].

**Overdose**

Symptoms of...
Read more


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Taste perversion US
  • Kind: experimental
    • Percent: 15
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: 14
  • Clinical Trial
    Taste perversion US
  • Kind: experimental
    • Percent: 10
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 7
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 7%
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 7%
  • Clinical Trial
    Headache US
  • Kind: experimental
    • Percent: 7%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: 5%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: 5%
  • Clinical Trial
    Abdominal Pain US
  • Kind: experimental
    • Percent: 5%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 4%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 4%
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: 4%
  • Clinical Trial
    Nausea US
  • Kind: experimental
    • Percent: 4%
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: 4%
  • Clinical Trial
    Diarrhea US
  • Kind: experimental
    • Percent: 4%
  • Clinical Trial
    Vomiting US
  • Kind: experimental
    • Percent: 3%
  • Clinical Trial
    Vomiting US
  • Kind: experimental
    • Percent: 3%
  • Clinical Trial
    Flatulence US
  • Kind: experimental
    • Percent: 3%
  • Clinical Trial
    Vomiting US
  • Kind: experimental
    • Percent: 3%
  • Clinical Trial
    Flatulence US
  • Kind: experimental
    • Percent: 3%
  • Clinical Trial
    Flatulence US
  • Kind: experimental
    • Percent: 3%
  • Clinical Trial
    Rhinitis US
  • Kind: experimental
    • Percent: 2
  • Clinical Trial
    Tongue discoloration US
  • Kind: experimental
    • Percent: 2
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Constipation US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Rash US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Rash US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Dizziness US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Rash US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Upper Respiratory Infection US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Acid Regurgitation US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Upper Respiratory Infection US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Upper Respiratory Infection US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Acid Regurgitation US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Acid Regurgitation US
  • Kind: experimental
    • Percent: 2%
  • Clinical Trial
    Flu syndrome US
  • Kind: experimental
    • Percent: 1
  • Clinical Trial
    Pharyngitis US
  • Kind: experimental
    • Percent: 1
  • Clinical Trial
    Asthenia US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Asthenia US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Asthenia US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Back Pain US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Cough US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Back Pain US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Back Pain US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Cough US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial
    Cough US
  • Kind: experimental
    • Percent: 1%
  • Clinical Trial

    Contraindications

    • Regions: US
    • Patient Conditions:
        • Name: Patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole
        • Drugbank Id: DBCOND0117161
    • Route:
      • Oral
    • Regions: US
    • With Drugs:
        • Name: Rilpivirine
        • Drugbank Id: DB08864

    Food Interactions

    • Avoid alcohol.
    • Take 30-60 minutes before meals.

    Interactions

    Type in a drug name to check for interaction with Omeprazole

    The metabolism of (R)-warfarin can be increased when combined with Omeprazole.
    The metabolism of (S)-Warfarin can be increased when combined with Omeprazole.
    The metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Omeprazole.
    The metabolism of 4-hydroxycoumarin can be increased when combined with Omeprazole.
    The metabolism of 4-Methoxyamphetamine can be decreased when combined with Omeprazole.
    The metabolism of 5-androstenedione can be increased when combined with Omeprazole.
    The metabolism of Omeprazole can be decreased when combined with 6-Deoxyerythronolide B.
    The metabolism of 6-O-benzylguanine can be increased when combined with Omeprazole.
    The metabolism of 7-ethyl-10-hydroxycamptothecin can be increased when combined with Omeprazole.
    The metabolism of 8-azaguanine can be increased when combined with Omeprazole.
    The metabolism of 8-chlorotheophylline can be increased when combined with Omeprazole.
    The metabolism of 9-aminocamptothecin can be increased when combined with Omeprazole.
    The metabolism of 9-Deazaguanine can be increased when combined with Omeprazole.
    The metabolism of 9-Methylguanine can be increased when combined with Omeprazole.
    The metabolism of Omeprazole can be increased when combined with Abatacept.
    The serum concentration of Abemaciclib can be increased when it is combined with Omeprazole.
    The metabolism of Omeprazole can be decreased when combined with Abiraterone.
    The metabolism of Omeprazole can be decreased when combined with Acalabrutinib.
    The serum concentration of Acebutolol can be increased when it is combined with Omeprazole.
    The metabolism of Aceclofenac can be decreased when combined with Omeprazole.

    References

    • 1 . Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. [PubMed: 17190895]
    • 2 . Castell D: Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother. 2005 Nov;6(14):2501-10. doi: 10.1517/14656566.6.14.2501 . [PubMed: 16259581]
    • 3 . Higuera-de-la-Tijera F: Efficacy of omeprazole/sodium bicarbonate treatment in gastroesophageal reflux disease: a systematic review. Medwave. 2018 Mar 14;18(2):e7179. doi: 10.5867/medwave.2018.02.7179. [PubMed: 29547594]
    • 4 . Welage LS, Berardi RR: Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):52-62; quiz 121-3. [PubMed: 10665250]
    • 5 . Cederberg C, Andersson T, Skanberg I: Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl. 1989;166:33-40; discussion 41-2. [PubMed: 2690330]
    • 6 . Strand DS, Kim D, Peura DA: 25 Years of Proton Pump Inhibitors: A Comprehensive Review. Gut Liver. 2017 Jan 15;11(1):27-37. doi: 10.5009/gnl15502. [PubMed: 27840364]
    • 7 . McTavish D, Buckley MM, Heel RC: Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs. 1991 Jul;42(1):138-70. doi: 10.2165/00003495-199142010-00008. [PubMed: 1718683]
    • 8 . Langtry HD, Wilde MI: Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs. 1998 Sep;56(3):447-86. doi: 10.2165/00003495-199856030-00012. [PubMed: 9777317]
    • 9 . Lewin MJ: Cellular mechanisms and inhibitors of gastric acid secretion. Drugs Today (Barc). 1999 Oct;35(10):743-52. [PubMed: 12973369]
    • 10 . Sachs G, Wallmark B: The gastric H+,K+-ATPase: the site of action of omeprazole. Scand J Gastroenterol Suppl. 1989;166:3-11. [PubMed: 2557669]
    • 11 . Sachs G, Shin JM, Howden CW: Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006 Jun;23 Suppl 2:2-8. doi: 10.1111/j.1365-2036.2006.02943.x. [PubMed: 16700898]
    • 12 . Sung JJ, Kuipers EJ, El-Serag HB: Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009 May 1;29(9):938-46. doi: 10.1111/j.1365-2036.2009.03960.x. [PubMed: 19220208]
    • 13 . Vcev A, Stimac D, Vceva A, Takac B, Pezerovic D, Ivandic A: High dose omeprazole plus amoxicillin and azithromycin in eradication of Helicobacter pylori in duodenal ulcers. Helicobacter. 1999 Mar;4(1):54-7. [PubMed: 10352088]
    • 14 . Scott DR, Sachs G, Marcus EA: The role of acid inhibition in Helicobacter pylori eradication. F1000Res. 2016 Jul 19;5. doi: 10.12688/f1000research.8598.1. eCollection 2016. [PubMed: 30023042]
    • 15 . Mobley HL: The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration. Aliment Pharmacol Ther. 1996 Apr;10 Suppl 1:57-64. [PubMed: 8730260]

    Recent Questions